Protagonist Therapeutics Beat Consensus Estimates

Protagonist Therapeutics (PTGX) reported earnings of $2.29 per share on revenue of $213.48 million for the second quarter ended June 2026. The consensus earnings estimate was $2.11 per share on revenue of $220.34 million. The company beat consensus estimates by 8.53% while revenue grew 3,749.17% on a year-over-year basis.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn's disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States.